These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19934279)

  • 1. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
    Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH
    Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
    Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
    Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
    Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
    Zhang YW; Staal B; Essenburg C; Su Y; Kang L; West R; Kaufman D; Dekoning T; Eagleson B; Buchanan SG; Vande Woude GF
    Cancer Res; 2010 Sep; 70(17):6880-90. PubMed ID: 20643778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
    Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.
    Zou HY; Li Q; Lee JH; Arango ME; Burgess K; Qiu M; Engstrom LD; Yamazaki S; Parker M; Timofeevski S; Cui JJ; McTigue M; Los G; Bender SL; Smeal T; Christensen JG
    Mol Cancer Ther; 2012 Apr; 11(4):1036-47. PubMed ID: 22389468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
    Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
    Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
    Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
    Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
    Ortiz-Zapater E; Lee RW; Owen W; Weitsman G; Fruhwirth G; Dunn RG; Neat MJ; McCaughan F; Parker P; Ng T; Santis G
    PLoS One; 2017; 12(1):e0170798. PubMed ID: 28141869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
    Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
    Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.
    Egile C; Kenigsberg M; Delaisi C; Bégassat F; Do-Vale V; Mestadier J; Bonche F; Bénard T; Nicolas JP; Valence S; Lefranc C; Francesconi E; Castell C; Lefebvre AM; Nemecek C; Calvet L; Goulaouic H
    Mol Cancer Ther; 2015 Feb; 14(2):384-94. PubMed ID: 25504634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.
    Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F; Zimmer Y
    Mol Cancer Ther; 2013 Nov; 12(11):2415-24. PubMed ID: 24061647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities.
    Wang Y; Zhan Z; Jiang X; Peng X; Shen Y; Chen F; Ji Y; Liu W; Shi Y; Duan W; Ding J; Ai J; Geng M
    Oncotarget; 2016 Jun; 7(25):38091-38104. PubMed ID: 27191264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
    J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration.
    Kim JW; Lee MN; Jeong BC; Oh SH; Kook MS; Koh JT
    Eur J Pharmacol; 2017 Jul; 806():10-17. PubMed ID: 28322831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.
    He CX; Ai J; Xing WQ; Chen Y; Zhang HT; Huang M; Hu YH; Ding J; Geng MY
    Acta Pharmacol Sin; 2014 Jan; 35(1):89-97. PubMed ID: 24241352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.